BridgeBio Oncology (BBOT) Director Peter Lebowitz Receives Award

What Happened

• Peter F. Lebowitz, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), received a derivative equity award covering 7,289 shares on 2026-06-16. The transaction is reported as an award/grant (code A) with an acquisition price of $0.00 (reported value $0). This is a compensation grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing, within typical reporting window).
• Reported terms: 7,289 derivative shares granted; acquisition price reported as $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the next Annual Meeting of Stockholders following the grant, subject to continued service (see footnote F1).
• Exhibit included: Exhibit 24 — Power of Attorney.

Context

• This is a derivative/compensation grant (stock option) that vests based on continued service and timing conditions; it does not represent an immediate open-market purchase or sale. Such awards are common for directors and indicate future potential ownership if vesting and any exercise conditions are met.